ArticleAngewandte Chemie (International ed. in English)2016
Noninvasive Staging of Kidney Dysfunction Enabled by Renal-Clearable Luminescent Gold Nanoparticles.
Article in Angewandte Chemie (International ed. in English), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Interface Self-Assembly of AuSmall (Weinheim an der Bergstrasse, Germany) · 2026Article
- Contrast-sparing CT using renal-clearable gold nanoclusters for early spatial mapping of renal dysfunction.Science advances · 2026Article
- NIR Excitation in Atomically Precise Nanoclusters via Two-Photon and Three-Photon Absorption.Accounts of chemical research · 2026Article
- Article
- Reno-protective CT contrast nanoagent targets proximal tubular epithelium for kidney disease imaging and repair in a mouse model.Nature communications · 2025Article
- Medical importance and pharmacokinetics of gold nanoparticles in the human body.Molecular cancer · 2025Review
- Blood Retention and Kidney Clearance of Renal-Clearable Gold Nanoparticles Strongly Correlate with Renal Injury Biomarkers.Angewandte Chemie (International ed. in English) · 2025Article
- Rapid discovery of drug-introduced multiple organ dysfunctionActa pharmaceutica Sinica. B · 2025Article
- Nanoparticle Transport in Proximal Tubules with Rhabdomyolysis-Induced Necrosis.Angewandte Chemie (International ed. in English) · 2025Article
- Research and Application Prospect of Nanomedicine in Kidney Disease: A Bibliometric Analysis From 2003 to 2024.International journal of nanomedicine · 2025Review
- Non-invasive in vivo sensing of bacterial implant infection using catalytically-optimised gold nanocluster-loaded liposomes for urinary readout.Nature communications · 2024Article
- Multivalent supramolecular fluorescent probes for accurate disease imaging.Science advances · 2024Article
- Gold Nanoparticle Transport in the Injured Kidneys with Elevated Renal Function Biomarkers.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Physiological principles underlying the kidney targeting of renal nanomedicines.Nature reviews. Nephrology · 2024Review
- Unveiling the photoluminescence dynamics of gold nanoclusters with fluorescence correlation spectroscopy.Nanoscale advances · 2024Article
- Atomically Precise Water-Soluble Gold Nanoclusters: Synthesis and Biomedical Application.Precision chemistry · 2023Review
- A sub-10-nm, folic acid-conjugated gold nanoparticle as self-therapeutic treatment of tubulointerstitial fibrosis.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Global, regional, and national burden of kidney dysfunction from 1990 to 2019: a systematic analysis from the global burden of disease study 2019.BMC public health · 2023Article
- Application of nanoparticles in the diagnosis and treatment of chronic kidney disease.Frontiers in medicine · 2023Review
- Tumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines.Materials today. Bio · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
As a "silent killer", kidney disease is often hardly detected at an early stage but can cause lethal kidney failure later on. Thus, a preclinical imaging technique that can readily differentiate between the stages of kidney dysfunction is highly desired for improving our fundamental understanding of kidney disease progression. Herein, we report that in vivo fluorescence imaging, enabled by renal-clearable near-infrared-emitting gold nanoparticles, can noninvasively detect kidney dysfunction, report on the dysfunctional stages, and even reveal adaptive function in a mouse model of unilateral obstructive nephropathy, which cannot be diagnosed with routine kidney function markers. These results demonstrate that low-cost fluorescence kidney functional imaging is highly sensitive and useful for the longitudinal, noninvasive monitoring of kidney dysfunction progression in preclinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.